News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Oct 31, 2002

  Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT

  Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
• Oct 30, 2002

  Insmed Incorporated Reports Third Quarter Results

  Insmed Incorporated Reports Third Quarter Results
• Oct 7, 2002

  Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine

  Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine
• Sep 23, 2002

  Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources

  Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources
• Sep 10, 2002

  Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -

  Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download